LYNX: A Novel Mobile App to Support Linkage to HIV/STI Testing PrEP for Young Men Who Have Sex With Men

NCT03177512 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2021-05-11

Study results available
· View outcomes & findings →

Summary

This study is testing the acceptability and feasibility of a highly interactive mobile application (app) to promote HIV/sexually transmitted infection (STI) testing and uptake of pre-exposure prophylaxis (PrEP) among young men who have sex with men (YMSM).

Conditions

  • HIV
  • Sexually Transmitted Diseases
  • Risk Reduction
  • Pre-Exposure Prophylaxis

Interventions

BEHAVIORAL

LYNX Mobile App

Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.

Sponsors & Collaborators

  • Cook County Health & Hospitals System

    collaborator OTHER
  • Duke University

    collaborator OTHER
  • Emory University

    collaborator OTHER
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH
  • San Francisco Department of Public Health

    collaborator OTHER_GOV
  • University of California, San Francisco

    collaborator OTHER
  • University of North Carolina, Chapel Hill

    collaborator OTHER
  • University of South Florida

    collaborator OTHER
  • Public Health Foundation Enterprises, Inc.

    lead OTHER

Principal Investigators

  • Albert Liu, M.D., MPH · Bridge HIV, San Francisco Department of Public Health

  • Hyman Scott, M.D., MPH · Bridge HIV, San Francisco Department of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
24 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-25
Primary Completion
2019-11-18
Completion
2019-11-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03177512 on ClinicalTrials.gov